DrugPatentWatch Database Preview
Drugs in Development Information for Fosbretabulin
» See Plans and Pricing
What is the drug development status for Fosbretabulin?
Fosbretabulin is an investigational drug.
There have been 18 clinical trials for Fosbretabulin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Neuroendocrine Tumors. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are two hundred and nineteen US patents protecting this investigational drug and one international patent.
Summary for Fosbretabulin
| US Patents | 219 |
| International Patents | 1,316 |
| US Patent Applications | 420 |
| WIPO Patent Applications | 1,044 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-03-01) |
| Vendors | 20 |
Recent Clinical Trials for Fosbretabulin
| Title | Sponsor | Phase |
|---|---|---|
| Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | Lowell Anthony, MD | Phase 1 |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | Mateon Therapeutics | Phase 2/Phase 3 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | Mateon Therapeutics | Phase 3 |
Clinical Trial Summary for Fosbretabulin
Top disease conditions for Fosbretabulin
Top clinical trial sponsors for Fosbretabulin
US Patents for Fosbretabulin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fosbretabulin | Start Trial | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (New Orleans, LA) | Start Trial |
| Fosbretabulin | Start Trial | Methods and devices for cellular transplantation | Sernova Corporation (London, Ontario, CA) | Start Trial |
| Fosbretabulin | Start Trial | Minimally toxic prodrugs | LIFE SCIENCES RESEARCH PARTNERS VZW (Leuven, BE) | Start Trial |
| Fosbretabulin | Start Trial | Pharmaceutical compositions comprising POH derivatives | NeOnc Technologies, inc. (Los Angeles, CA) | Start Trial |
| Fosbretabulin | Start Trial | Methods of obtaining geometry from images | Bio-Tree Systems, Inc. (Framingham, MA) | Start Trial |
| Fosbretabulin | Start Trial | EGFR-binding modular recognition domains | Zyngenia, Inc. (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fosbretabulin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fosbretabulin | World Intellectual Property Organization (WIPO) | WO2015153252 | 2034-03-31 | Start Trial |
| Fosbretabulin | Australia | AU2010286531 | 2029-08-28 | Start Trial |
| Fosbretabulin | Canada | CA2772375 | 2029-08-28 | Start Trial |
| Fosbretabulin | China | CN102596273 | 2029-08-28 | Start Trial |
| Fosbretabulin | Cyprus | CY1119719 | 2029-08-28 | Start Trial |
| Fosbretabulin | Denmark | DK2470228 | 2029-08-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
